Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Breast Cancer Metastatic × ribociclib × Clear all

Phase

Status

Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 24 Neoplasms 4 Glioma 4 Ovarian Neoplasms 3 Melanoma 3 Glioblastoma 3 Rhabdoid Tumor 2 Prostatic Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Neoplasm Metastasis 2 Medulloblastoma 2 Lymphoma 2 Liposarcoma 2 Fallopian Tube Neoplasms 2 Diffuse Intrinsic Pontine Glioma 2 Brain Neoplasms 2 Astrocytoma 2 Thymus Neoplasms 1 Teratoma 1 Solid Tumors Harboring a BRAF V600 Mutation 1 Sarcoma, Synovial 1 Sarcoma 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Pinealoma 1 Osteitis Deformans 1 Oligodendroglioma 1 Non functioning pancreatic endocrine tumor 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1

Interventions

Letrozole 3 exemestane 2 Fulvestrant 2 Anastrozole 2 ribociclib 1 irinotecan sucrosofate 1 abemaciclib 1 Trastuzumab 1 Paclitaxel 1 Liposomes 1 Irinotecan 1 Everolimus 1 Docetaxel 1 Cyclophosphamide 1 Cell Separation 1 Capecitabine 1 Aromatase Inhibitors 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03555877 2023-07-07

AMICA

GBG Forschungs GmbH

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡